2323

# Expert Assessment: Metabolic Reprogramming to Reverse Senescence in Neurodegeneration

## Druggability: Mixed

The NAMPT→SIRT1→PGC1α axis is **partially druggable but with significant caveats**:

- **NAD+ precursors (NMN, NR)**: Highly tractable—ChromaDex's Tru Niagen (NR) and multiple NMN formulations are in trials. Both have acceptable safety profiles and oral bioavailability, though CNS penetration remains uncertain.
- **NAMPT direct activators**: Theoretically targetable as an enzyme, but no potent, selective pharmacological activators have reached clinical development. The NAD+ precursor approach essentially circumvents this bottleneck.
- **SIRT1**: Direct activators (resveratrol-era compounds) failed due to misleading assay artifacts. No viable clinical SIRT1 activators exist—this node remains undruggable via small molecules.
- **PGC1α**: Transcription co-activator with no direct small-molecule interface; typically targeted through upstream pathways or experimental gene therapy approaches.

## Fundamental Feasibility Concerns

The core scientific premise carries **substantial risk**. "Reversing senescence" contradicts the operational definition of senescence as irreversible cell cycle arrest. Whether truly arrested neurons can be coaxed back to functional fidelity is unknown. Key unknowns:

- **CNS delivery**: Peripheral NAD+ elevation does not reliably predict brain NAD+ levels due to blood-brain barrier